Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:5.99.1.3 (
topoisomerase
)
9,911
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In two human cancer cell lines, the breast mcf-7 and the T-cell leukemia MOLT4, we investigated the cytotoxicity of four antineoplastic agents having different mechanisms of action. We selected doxorubicin as a DNA-
topoisomerase
II inhibitor, FCE24517 (a Distamycin A derivative) as a DNA minor groove binder with specificity for AT bases, melphalan as an alkylating agent and cis-platinum as an alkylating agent able to form DNA-intrastrand crosslinks. From the cytotoxicity experiments a moderately toxic (less than 10% of growth inhibition) and a highly toxic (about 75% growth inhibition) dose were selected to evaluate the expression of genes involved in cell proliferation and in cell response to extracellular insults. The expression was evaluated at early times (60 min.) and 24 hrs. after treatment. At the concentrations utilized in both cell lines we could not find any alteration in the expression of p53, gas-1 and heat shock 70. After melphalan treatment down regulation of c-myc and of the
H2A histone
was seen at high doses, while no significant alteration of their expression was seen with the other drugs.
...
PMID:Effects of DNA damaging agents on gene expression in two human cancer cell lines. 829 34